Text Size

Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl

Iwamura R., Tanaka M., Okanari E., Kirihara T., Odani-Kawabata N., Shams N., Yoneda K.


  • 2018
  • Journal of Medicinal Chemistry
View publication
  • Therapeutic Area

    Glaucoma

  • Technology

    Other

  • Categories

    Preclinical development

  • Affiliations

    Pharmaceuticals Research Laboratory, UBE Industries, Ltd., 1978-5 Kogushi, Ube Yamaguchi, 755-8633, Japan; R and D Division, Santen Pharmaceutical Co., Ltd., Grand Front Osaka Tower A 4-20, Ofukacho, Kita-ku. Osaka, 530-8552, Japan; R and D Division, Santen Inc., 6401 Hollis Street, Emeryville, CA 94608, United States

Related Publications

A Study of 24-h Efficacy and Safety of Sepetaprost vs. Latanoprost in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension

Konstas A.G.; Garhöfer G.; Lübke Y.; Voykov B.; Ropo A.


Valproic Acid Application to Modify Post Surgical Fibrosis in a Model of Minimally Invasive Bleb Surgery

Lo P.F.; Gunawan M.; Yap Z.L.; Leong C.; Kwek F.; Varadarajan J.; Wang X.; Kageyama M.; Wong T.T.


The rate of failure of trabeculectomy and tube shunt surgery in eyes with uveitic glaucoma and ocular hypertension: The purpose of this study is to look at the outcomes of trabeculectomy and tube shunt surgery in a large cohort of patients with uveitis

Groth S.L.; Newcomb C.W.; Yang W.; Payal A.; Begum H.; Khachatryan N.; Kaçmaz R.O.; Dreger K.A.; Rosenbaum J.T.; Nida Sen H.; Suhler E.B.; Thorne J.E.; Bhatt N.P.; Foster C.S.; Jabs D.A.; Levy-Clarke G.A.; Buchanich J.M.; Ying G.S.; Kempen J.H.; Gangaputra S.;


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022